Ampreloxetine

Investigational once-daily norepinephrine reuptake inhibitor

For symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients

New Ampreloxetine Study in Patients with MSA

Phase 3 registrational study

Study 0197: 20 weeks

12-week open-label; 8-week randomized, double-blind, placebo-controlled withdrawal



Long-term extension

Study 0197: 2 years

Long-term, open-label



- **CYPRESS study initiation planned for first quarter of 2023**

MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension.

Offering Hope to MSA Patients with Symptomatic nOH

Study 0197 (CYPRESS): Phase 3 randomized withdrawal study in patients with MSA
Primary endpoint: change in OHSA composite score



MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; OHSA, orthostatic hypotension symptom assessment; RWD, randomized withdrawal design.